EMT6 Mouse Model
Breast cancer is the second most common cancer diagnosed in women. Collectively, 250,000 new cases, and 50,000 deaths are recorded annually in the United States, primarily for advanced aggressive metastatic variations.
Mammary carcinomas are a type of cancer that features characteristics of lobular and ductal carcinoma; EMT6 is an immortal mouse mammary carcinoma cell line.
The syngeneic mouse model was produced through hyperplastic mammary alveolar nodule implantation of an exogenous mammary fat pad.
EMT6 expresses PD-L1, and adopts pulmonary metastasis readily upon implantation.
Metastatic potential
Our model uses BALB/c mice, and reflects the tumorigenicity of aggressive metastatic mammary cancers, providing a valuable platform for drug discovery.
Fast-growing tumors
EMT6 is distinguished by high immunogenicity and rapid tumor kinetics.
Fully Characterized Model
We have characterized EMT6 mouse mammary carcinoma in both syngeneic (flank) and orthotopic models.
EMT6 Syngeneic Breast Cancer Model
The EMT6 is a triple-negative mammary carcinoma with a less aggressive metastatic potential and is well suited for immuno-oncology combination studies.
EMT6 was established from transplantable murine mammary carcinoma from a BALB/cCRGL mouse after hyperplastic mammary alveolar nodule implantation. The resulting tumor was propagated in BALB/cKa mice and isolated from clonal expansion.
Used as a powerful immuno-oncology tool due to the favorable immune profile and responsiveness to immune checkpoint blockades. EMT6 syngeneic models are suitable for cytotoxic therapy along with immune-modulating agents.
For stage IV breast cancer, the standard of care is systemic drug therapies such as hormone therapy, chemotherapy, targeted drugs, immunotherapy and a combination of these. In some instances surgery and radiation therapy may be useful.